Phase II of sunitinib in chemo-naive (ED) or sensitive relapse SCLC

• Research type

  Research Study

• Full title

  Phase II study of Sunitinib (SU011248) in patients with small cell lung cancer who are either chemo-naive (extensive disease) or have a 'sensitive' relapse.

• IRAS ID

  8813

• Contact name

  Mary O'Brien

• Sponsor organisation

  European Organisation for Research and Treatment of Cancer

• Eudract number

  2006-002485-19

• ISRCTN Number

  n/a

• Research summary

  This is an open, non-randomised phase II study looking at response to the drug Sunitinib in patients with small cell lung cancer who have either extensive disease that has never been treated with chemotherapy, or who have a 'sensitive' relapse (and extensive or limited disease). Patients will be assessed for progression of disease at frequent intervals using the RECIST criteria. Treatment will stop at diagnosis of disease progression. The role of new imaging (FDG-CT-PET) and tumour markers in blood and tumour tissue in the assessment of early response to the drug treatment will also be examined.

• REC name

  London - Surrey Borders Research Ethics Committee

• REC reference

  09/H0806/36

• Date of REC Opinion

  18 Aug 2009

• REC opinion

  Further Information Favourable Opinion